RxDoctor Payments Data

Nicole Newingham, DO

Family Medicine · Warminster, PANPI 1083063895

Payments from drug & device makers

$744in general payments, 2019–2025

Across 31 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$190
  • Teva Pharmaceuticals USA, Inc.$140
  • Sanofi$98
  • Lilly USA, LLC$94
  • Amgen$81
  • Merck$30
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$744 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$75,372
Medicare patients
329
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$93,306
JanuviaSitagliptin Phosphate48$60,279
EliquisApixaban32$52,559
OzempicSemaglutide28$46,235
XareltoRivaroxaban25$29,393
FarxigaDapagliflozin Propanediol16$22,957
MounjaroTirzepatide13$22,367
Breo ElliptaFluticasone/Vilanterol16$11,414
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid40$11,057
Atorvastatin Calcium728$9,662
ByettaExenatide11$9,201
SynthroidLevothyroxine Sodium89$7,513
Levothyroxine Sodium375$4,977
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,736
Losartan Potassium203$3,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$30$60,27948 claims
PfizerEliquis$26$52,55932 claims
Novo NordiskOzempic$190$46,23528 claims
AstraZenecaFarxiga, Byetta$15$32,15827 claims
Lilly USA, LLCMounjaro$94$22,36713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Warminster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →